Medicxi Ventures Management (Jersey) LTD Phathom Pharmaceuticals, Inc. Transaction History
Medicxi Ventures Management (Jersey) LTD
- $660 Million
- Q3 2025
A detailed history of Medicxi Ventures Management (Jersey) LTD transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Medicxi Ventures Management (Jersey) LTD holds 7,464,572 shares of PHAT stock, worth $110 Million. This represents 12.93% of its overall portfolio holdings.
Number of Shares
7,464,572
Previous 7,464,572
-0.0%
Holding current value
$110 Million
Previous $71.6 Million
19.29%
% of portfolio
12.93%
Previous 20.28%
Shares
5 transactions
Others Institutions Holding PHAT
# of Institutions
149Shares Held
65.3MCall Options Held
1.15MPut Options Held
170K-
Frazier Life Sciences Management, L.P. Menlo Park, CA12.5MShares$183 Million6.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.08MShares$74.6 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.86MShares$56.8 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$51.4 Million50.16% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.22MShares$47.2 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $575M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...